Arrowstreet Capital’s Pfizer PFE Stock Holding History

Arrowstreet Capital’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-702,992	Closed	-$17.5M	–	2041
2025 Q4	$17.5M	Sell	702,992 -17,862,459	-96%	-$450M	0.01%	773
2025 Q3	$473M	Sell	18,565,451 -153,504	-0.8%	-$3.79M	0.3%	71
2025 Q2	$454M	Buy	18,718,955 +5,662,309	+43%	+$132M	0.32%	65
2025 Q1	$331M	Buy	+13,056,646	New	+$342M	0.27%	77
2023 Q4	–	Sell	-25,983	Closed	-$862K	–	1523
2023 Q3	$862K	Sell	25,983 -287,658	-92%	-$10.2M	﹤0.01%	1015
2023 Q2	$11.5M	Sell	313,641 -2,516,994	-89%	-$98M	0.01%	484
2023 Q1	$115M	Buy	2,830,635 +2,808,104	+12,463%	+$121M	0.15%	158
2022 Q4	$1.15M	Sell	22,531 -122,027	-84%	-$5.85M	﹤0.01%	996
2022 Q3	$6.33M	Buy	+144,558	New	+$7.02M	0.01%	605
2022 Q2	–	Sell	-3,602,766	Closed	-$187M	–	1382
2022 Q1	$187M	Buy	3,602,766 +2,522,310	+233%	+$131M	0.23%	109
2021 Q4	$63.8M	Sell	1,080,456 -23,744	-2%	-$1.18M	0.08%	252
2021 Q3	$47.5M	Buy	1,104,200 +794,100	+256%	+$35.2M	0.06%	329
2021 Q2	$12.1M	Buy	310,100 +225,500	+267%	+$8.77M	0.01%	780
2021 Q1	$3.06M	Sell	84,600 -906,799	-91%	-$32.2M	﹤0.01%	1393
2020 Q4	$36.5M	Buy	991,399 +941,439	+1,884%	+$34.5M	0.05%	371
2020 Q3	$1.74M	Sell	49,960 -393,719	-89%	-$13.8M	﹤0.01%	1616
2020 Q2	$13.8M	Sell	443,679 -3,070,696	-87%	-$104M	0.03%	654
2020 Q1	$109M	Buy	3,514,375 +3,391,584	+2,762%	+$116M	0.31%	59
2019 Q4	$4.56M	Buy	122,791 +52,595	+75%	+$1.87M	0.01%	882
2019 Q3	$2.39M	Buy	+70,196	New	+$2.55M	0.01%	923
2019 Q2	–	Sell	-113,477	Closed	-$4.57M	–	1637
2019 Q1	$4.57M	Buy	113,477 +56,315	+99%	+$2.26M	0.01%	818
2018 Q4	$2.37M	Buy	+57,162	New	+$2.37M	0.01%	743
2018 Q1	–	Sell	-65,664	Closed	-$2.26M	–	1284
2017 Q4	$2.26M	Buy	65,664 +22,977	+54%	+$783K	0.01%	788
2017 Q3	$1.45M	Buy	42,687 +9,064	+27%	+$291K	﹤0.01%	767
2017 Q2	$1.07M	Buy	+33,623	New	+$1.06M	﹤0.01%	768
2016 Q3	–	Sell	-735,587	Closed	-$24.6M	–	1585
2016 Q2	$24.6M	Buy	+735,587	New	+$23.5M	0.08%	240
2016 Q1	–	Sell	-1,849,591	Closed	-$56.6M	–	1480
2015 Q4	$56.6M	Sell	1,849,591 -456,139	-20%	-$14.3M	0.26%	84
2015 Q3	$68.7M	Buy	2,305,730 +928,574	+67%	+$29.8M	0.33%	64
2015 Q2	$43.8M	Buy	+1,377,156	New	+$44.9M	0.25%	106
2015 Q1	–	Sell	-2,362,093	Closed	-$69.8M	–	1173
2014 Q4	$69.8M	Sell	2,362,093 -4,375,077	-65%	-$125M	0.4%	57
2014 Q3	$189M	Buy	6,737,170 +562,815	+9%	+$15.8M	1.02%	19
2014 Q2	$174M	Buy	6,174,355 +1,899,823	+44%	+$54.2M	0.89%	25
2014 Q1	$130M	Sell	4,274,532 -5,420,735	-56%	-$162M	0.79%	29
2013 Q4	$282M	Buy	9,695,267 +263,470	+3%	+$7.67M	1.53%	5
2013 Q3	$257M	Buy	9,431,797 +3,160,623	+50%	+$86M	1.63%	6
2013 Q2	$167M	Buy	+6,271,174	New	+$173M	1.24%	15

Other funds holding PFE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Arrowstreet Capital's PFE Position: Q1 2026 in Review

Arrowstreet Capital sold out of Pfizer (PFE) in Q1 2026, closing a stake of 702,992 shares — an estimated $17.5M sold.

Arrowstreet Capital first reported a position in PFE in Q2 2013 and held it in 36 quarters. The position peaked at $473M in Q3 2025. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

Arrowstreet Capital reported no remaining Pfizer position as of Q1 2026 after selling out during the quarter.
Arrowstreet Capital sold 702,992 Pfizer shares in Q1 2026, an estimated $17.5M.
Arrowstreet Capital first reported a position in Pfizer in Q2 2013 and held it in 36 quarters.
Arrowstreet Capital's Pfizer position peaked at $473M in Q3 2025.
2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.